Abstract
Introduction
Ataxia telangiectasia (AT) is an autosomal recessive multisystem disorder characterized by variable immunodeficiency, progressive neurodegeneration, occulocutaneous telangiectasia, and an increased susceptibility to malignancies. This study was designed to study the role of proapoptotic BAK, BAX, and NBK/BIK genes in a group of patients with AT to elucidate the possible role of these genes in progression of malignancies in this disease.
Materials and Methods
Fifty Iranian patients with AT were investigated in this study. The entire coding regions of the BAK gene (exons 2–6), NBK/BIK gene (exons 2–5), and BAX gene (exons 1–7) were amplified using polymerase chain reaction (PCR). The PCR products were separated by 2% agarose gel electrophoresis, and all positive samples were verified by direct sequencing of PCR products using the same primers used for PCR amplification, BigDye chemistry, and Avent 3100 Genetic Analyzer following the manufacturer’s instructions (Applied Biosystems).
Results
Eight of fifty Iranian AT patients (16%) exhibited a C > T transition in exon 2 (c342C > T) of the BAK gene, while none of the healthy controls had such alteration (P = 0.0001). Higher frequency of another nucleotide substitution in the noncoding region of exon 7 in BAX gene (6855G > A) was also identified in 68% of the patient group versus 24% in the controls (P < 0.0001). Sequence alteration in intronic region of the NBK/BIK gene IVS4-12delTC was observed in 52% of AT patients, which was significantly higher than 20% in the control group (P = 0.0023). Another variant IVS1146C > T in the intronic region of the BAX gene was found in 78% of patients, which was significantly higher than 10% in the controls (P < 0.0001). Frequency of alteration in intronic region of exon 3 of the BAX gene (IVS3 + 14A > G) was also significantly higher in the AT patients (P < 0.0001).
Discussion
Several alterations in the proapoptotic genes BAK, NBK/BIK, and BAX were found in our study, which could elucidate involvement of the mitochondrial pathway mediated apoptosis in accelerating and developing of cancers and in immunopathogenesis of AT. Such altered apoptosis in AT could play some roles in developing cancers in this group of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yeganeh M, Gambineri E, Abolmaali K, Tamizifar B, Espanol T. Other well-defined immunodeficiencies. In: Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary immunodeficiency diseases: definition, diagnosis and management, vol 1. Berlin: Springer; 2008. p. 251–90.
Sandoval N, Platzer M. Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet. 1999;8:69–79.
Gatti RA. Ataxia-Telangiectasia. http://www.ncbi.nih.gov.book. Gene Reviews 2005.
Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–82.
Babaei M, Mitui M, Olson ER, Gatti RA. ATM haplotypes and associated mutations in Iranian patients with ataxia-telangiectasia: recurring homozygosity without a founder haplotype. Hum Genet. 2005;117:101–6.
Martini M, D’Alò F, Hohaus S, Leone G, Larocca LM. Absence of structural mutations of the Bak gene in B cell lymphomas. Haematologica. 2002;87:661–2.
Cartron PF, Juin P, Oliver L, Martin S, Meflah K, Vallette FM. Nonredundant role of Bax and Bak in Bid-mediated apoptosis. Mol Cell Biol. 2003;23:4701–12.
Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–33.
Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, et al. Mutation of the Bak gene in human gastric and colorectal cancers. Cancer Res. 2000;60:4328–30.
Kim SP, Hwang MS, Cho YR, Kwon SY, Kang YN, Kim IH, et al. Mutation of Bak gene are infrequent in advanced gastric adenocarcinomas in Koreans. Cancer Lett. 2003;195:87–91.
Wani KM, Huilgol NG. Genetic alterations in coding region of the Bak gene in uterine cervical carcinoma. Br J Cancer. 2003;88:1584–6.
Peng H, Aiello A, Packham G, Isaacson PG, Pan L. Infrequent Bax gene mutations in B cell lymphomas. J Pathol. 1998;186:378–82.
Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M. Impairment of the pro apoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res. 1999;59:2034–7.
Suleka V, Budarf ML. Structural analysis of human pro-apoptotic gene BIK. Gene. 2000;254:157–62.
Arena V, Martini M, Luongo M, Capelli A, Larocca LM. Mutations of Bik gene in human peripheral B cell lymphomas. Genes Chrom Cancer. 2003;38:91–6.
Takagi M, Delia D. Defective control of apoptosis, radiosensivity, and spindle checkpoint in ataxia telangiectasia. Cancer Res. 1998;58:4923–9.
Moin M, Aghamohammadi A, Kouhi A, Tavassoli S, Rezaei N, Ghaffari SR, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37:21–8.
Reed JC. Bcl-2 family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322–30.
Cartron PF, Juin P, Oliver L, Meflah K, Vallette FM. Impact of proapoptotic proteins Bax and Bak in tumor progression and rerponse to treatment. Expert Rev Anticancer Ther. 2003;3:563–70.
Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Slöetjes AW, de Witte T, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 1998;91:2991–7.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967–9.
Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a target region of allelic loss to a 0.5 cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology. 1999;117:831–7.
García N, Salamanca F, Astudillo-de la Vega H, Curiel-Quesada E, Alvarado I, Peñaloza R, et al. A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. BMC Cancer. 2005;5:93.
Eberle J, Hossini AM. Expression and function of bcl-2 proteins in melanoma. Curr Genomics. 2008;9:409–19.
Eberle J, Fecker LF, Hossini AM, Kurbanov BM, Fechner H. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol. 2008;17:1–11.
Fernet M, Angele S, Dörk T, Hall J. Variation in radiation-induced apoptosis in ataxia-telangiectasia lymphoblastoid cell lines. Int J Radiat Biol. 2003;79:193–202.
Acknowledgment
The authors are very grateful for all colleagues in Medical School of Hannover (Hannover, Germany) for their kind help and advices in the laboratory, and all the patients and their families for their kind collaboration in this study. We would like to thank Dr. Ali Rabbani for his help and support.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s10875-010-9390-9
Rights and permissions
About this article
Cite this article
Isaian, A., Bogdanova, N.V., Houshmand, M. et al. BAK, BAX, and NBK/BIK Proapoptotic Gene Alterations in Iranian Patients with Ataxia Telangiectasia. J Clin Immunol 30, 132–137 (2010). https://doi.org/10.1007/s10875-009-9340-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-009-9340-6